Is MDGL or MIST more undervalued in 2026?

CirclFi compares Madrigal Pharmaceuticals, Inc. (MDGL) and Milestone Pharmaceuticals Inc. (MIST) using 13 institutional-grade valuation models. MDGL has a Quality of Company score of 6.9/10 while MIST scores 3.6/10.

Which is a better buy — MDGL or MIST?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MDGL and MIST valuations compare?

MDGL at $497.27 and MIST at $1.42 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MDGL vs MIST Valuation Comparison 2026 — Intrinsic Value Analysis

MDGL

Pharmaceutical Preparations

Madrigal Pharmaceuticals, Inc.

Quality

6.9

out of 10

Value Trap

SAFE

Price

$497.27

Last close

Models

12/13

Active

MIST

Pharmaceutical Preparations

Milestone Pharmaceuticals Inc.

Quality

3.6

out of 10

Value Trap

LOW

Price

$1.42

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	MDGL Fair Value	MDGL Upside	MIST Fair Value	MIST Upside
Bayesian DCF	Intrinsic	$172.14	-65.4%	$0.51	-63.7%
Earnings Power Value	Intrinsic	$237.47	-53.7%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$27.01	-94.6%	$0.23	-83.5%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MDGL vs MIST — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MDGL vs MIST — Which Stock Is More Undervalued?

MDGL scores higher with a 6.9/10 quality rating vs MIST's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Madrigal Pharmaceuticals, Inc. (MDGL) and Milestone Pharmaceuticals Inc. (MIST) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MDGL currently trades at $497.27 with a QOC of 6.9/10, while MIST trades at $1.42 with a QOC of 3.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).